| 3.84 0.22 (6.08%) | 11-05 15:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.11 | 1-year : | 5.66 |
| Resists | First : | 4.38 | Second : | 4.84 |
| Pivot price | 4.09 |
|||
| Supports | First : | 3.61 | Second : | 3.01 |
| MAs | MA(5) : | 3.92 |
MA(20) : | 4.17 |
| MA(100) : | 3.98 |
MA(250) : | 9.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 16.2 |
| RSI | RSI(14): 41.9  |
|||
| 52-week | High : | 53.09 | Low : | 0.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CDIO ] has closed above bottom band by 13.3%. Bollinger Bands are 0.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.92 - 3.96 | 3.96 - 3.98 |
| Low: | 3.56 - 3.59 | 3.59 - 3.61 |
| Close: | 3.58 - 3.63 | 3.63 - 3.66 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Tue, 28 Oct 2025
Cardio Diagnostics (NASDAQ: CDIO) to host Wisdom Wednesdays with YMCA starting Nov 2025 - Stock Titan
Tue, 21 Oct 2025
Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States - Business Wire
Wed, 15 Oct 2025
Cardio Diagnostics shareholders approve director slate and key proposals at annual meeting - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.63e+006 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.85e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -22 % |
| Return on Assets (ttm) | 457.5 % |
| Return on Equity (ttm) | -54.2 % |
| Qtrly Rev. Growth | 19510 % |
| Gross Profit (p.s.) | -1.75 |
| Sales Per Share | -34.16 |
| EBITDA (p.s.) | 6821.67 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.12 |
| Price to Cash Flow | 1.92 |
| Dividend | 0 |
| Forward Dividend | 39570 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|